23andMe Holding Co.

genetics, and then working with customers and patients, that that can really potentially transform that space. And we believe that 23andMe is really uniquely placed to take advantage of this. For example, we believe it will help us in our PRS research. automating functions within the business at scale, and also helping us, I think, interestingly, in different ways with our drug discovery and development process. So, you know, we're optimistic this is going to enable us to deliver products and services at scale in the way that we think we're uniquely placed to take advantage of this in a competitive way at the company. Very exciting.

Okay. And final question. Considering your financial position, do you believe you will require a dilutive capital raise anytime in the future?

23andMe has a strong current cash position with $387 million in cash and cash equivalents as of March 31st, 2023. Our four-year adjusted EBITDA deficit is projected to be in the range of $170 to $195 million for fiscal year 2024. And that number, as I mentioned earlier, you know, basically assumes that we're going to continue to advance all of our current therapeutic assets and does not assume any additional revenue from new strategic partnerships. And nor does it include any savings, you know, from any potential cost reduction and initiatives that I had mentioned earlier. You know, our adjusted EBITDA is our best proxy for cash burn. And so that just gives you a sense of what our cash position and runway looks like. And it's a reasonably good period of time that will give us the ability to execute upon a lot of our goals on the consumer side as well as on our therapeutics portfolio.